Expanded GLP-1 Medication Access Through Formulary Updates

By HEOR Staff Writer

May 29, 2026

GLP-1 Medication Access

CVS Caremark’s latest formulary changes are poised to strengthen GLP-1 Medication Access for commercial plan members by restoring coverage for select weight-management therapies.

Effective October 1, 2026, Zepbound returns as a preferred option on template formularies for sponsors that elect coverage, while Foundayo loses its new-to-market block on June 1, 2026. These moves expand GLP-1 Medication Access without removing plan sponsors’ ability to tailor benefits.

Negotiated Savings Drive Affordability

Direct manufacturer negotiations delivered double-digit year-over-year net-cost reductions, allowing the reintroduction of Zepbound and addition of an oral GLP-1 agent. The resulting flexibility helps sponsors balance member needs with overall plan sustainability.

CVS Caremark negotiates acquisition prices and placement decisions on behalf of employers and health plans, using independent Pharmacy & Therapeutics review to weigh clinical value against cost.

Path to Sustainable Reimbursement

Targeted pricing agreements reduce pressure for coverage limits and support more durable market access for high-demand therapies.

Subscribe to Syenza Newsletter
Reference url

Recent Posts

comparative effectiveness research
Integration of Comparative Effectiveness Research into Drug Pricing Frameworks

By João L. Carapinha

Contemporary comparative effectiveness research plays a vital role in supporting federal and state drug pricing programs by highlighting real-world benefits, yet persistent challenges and unclear guidance continue to limit its integration. Core principles of evidence evaluation, research question...
European pharmacists preparation
European Pharmacists Preparation for Health Crisis Response

By João L. Carapinha

European pharmacists preparation ensures that community networks remain operational during health crises, enabling continuous patient care amid pandemics and infrastructure failures. The recently published PGEU position paper outlines seven priorities that integrate pharmacies into governance str...
Imfinzi bladder cancer approval
Imfinzi Bladder Cancer Approval Marks Breakthrough in Immunotherapy

By HEOR Staff Writer

The Imfinzi bladder cancer approval by the FDA now offers a new immunotherapy option for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer when combined with standard BCG induction and maintenance therapy. This Imfinzi bladder cancer approval stems from the POTOMAC Phase III ...